相关实验视频
Updated: Sep 8, 2025

08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
40.5K
新兴的喘和过敏疾病的全身治疗方法:新技巧,相同的狗?
Alessandra Tomasello1, Stanley J Szefler2, Katherine N Cahill3
1Research Fellow, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center.
The journal of allergy and clinical immunology. In practice
|September 5, 2025
概括
新的喘和过敏治疗除了针对2型炎症以外的各种免疫路径. 研究正在探索新疗法,但在生物标志物识别和针对非T2机制的个性化护理方面仍然存在挑战.
科学领域:
- 免疫学
- 对过敏的研究
- 临床治疗方法
背景情况:
- 喘和过敏性疾病是复杂而异质的.
- 第二类 (T2) 炎症是一个关键因素,但不是唯一的驱动因素.
- 进步需要探索新的治疗策略.
研究的目的:
- 批判性地审查正在进行的临床试验和喘和过敏症的新证据.
- 总结四个机制类别的系统性治疗方法.
- 评估新方法的治疗潜力和局限性.
主要方法:
- 对新出现的全身治疗方法进行系统评估.
- 基于四种机制路径进行分类:T2细胞因子抑制剂,警示剂阻断剂,效应细胞调节剂和非传统/非T2炎症标.
- 临床试验数据和科学文献的分析.
主要成果:
- 几种新疗法显示出有前途,特别是对于高T2喘表型.
- 治疗针对不同的免疫路径,包括T2细胞因子,警示蛋白和效应细胞.
- 在预测生物标志物发现,长期安全性评估和解决非T2炎症方面发现的挑战.
结论:
- 精确治疗策略需要进一步研究以优化不同患者群体的结果.
- 解决生物标志物识别和非T2机制方面的知识差距至关重要.
- 为指导未来的研究提供了结果测量的建议.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
446
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
446
Drugs Used in Lower Respiratory Disorders: Overview
573
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
573
Asthma: Pathogenesis and Management
573
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
573
Antiasthma Drugs: Leukotriene Modifiers
453
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
453
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Asthma-II: Pathophysiology and Classification
2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K

